MWNA
VRTX icon

Marshall Wace North America’s Vertex Pharmaceuticals VRTX Stock Holding History

Marshall Wace North America’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$81.9M Sell
451,406
-128,419
-22% -$25.1M 0.35% 57
2021
Q2 		$117M Sell
579,825
-407,463
-41% -$85.2M 0.49% 41
2021
Q1 		$212M Buy
987,288
+272,560
+38% +$59.9M 0.88% 12
2020
Q4 		$169M Buy
714,728
+615,362
+619% +$141M 0.76% 16
2020
Q3 		$27M Sell
99,366
-140,898
-59% -$38.9M 0.17% 149
2020
Q2 		$69.8M Sell
240,264
-47,636
-17% -$12.9M 0.46% 50
2020
Q1 		$68.5M Sell
287,900
-301,418
-51% -$69.1M 0.52% 57
2019
Q4 		$129M Sell
589,318
-163,350
-22% -$33.1M 0.62% 40
2019
Q3 		$128M Sell
752,668
-132,322
-15% -$23.4M 0.73% 37
2019
Q2 		$162M Buy
884,990
+92,983
+12% +$16.3M 1.01% 22
2019
Q1 		$146M Buy
792,007
+291,952
+58% +$53.9M 1.03% 19
2018
Q4 		$82.9M Sell
500,055
-304,706
-38% -$52.8M 0.8% 29
2018
Q3 		$155M Sell
804,761
-583,039
-42% -$104M 1.07% 21
2018
Q2 		$236M Buy
1,387,800
+727,532
+110% +$113M 1.33% 8
2018
Q1 		$108M Sell
660,268
-162,620
-20% -$26.6M 0.54% 38
2017
Q4 		$123M Buy
822,888
+256,709
+45% +$38M 0.68% 23
2017
Q3 		$86.1M Buy
566,179
+145,864
+35% +$22M 0.54% 21
2017
Q2 		$54.2M Sell
420,315
-4,248
-1% -$511K 0.4% 55
2017
Q1 		$46.3M Buy
+424,563
New +$37.4M 0.37% 79

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Marshall Wace North America's VRTX Position: Q3 2021 in Review

Marshall Wace North America reduced its Vertex Pharmaceuticals (VRTX) stake by 22% in Q3 2021, selling an estimated $25.1M and leaving 451,406 shares worth $81.9M. The position accounts for 0.35% of the portfolio, ranked #57.

Marshall Wace North America first reported a position in VRTX in Q1 2017 and has held it in 19 quarters since. The position peaked at $236M in Q2 2018. 935 funds tracked by Wall St. Rank hold VRTX as of Q3 2021.

  • Marshall Wace North America held 451,406 shares of Vertex Pharmaceuticals worth $81.9M as of Q3 2021.
  • Marshall Wace North America sold 128,419 Vertex Pharmaceuticals shares in Q3 2021, an estimated $25.1M.
  • Vertex Pharmaceuticals made up 0.35% of Marshall Wace North America's portfolio in Q3 2021, its #57 holding.
  • Marshall Wace North America first reported a position in Vertex Pharmaceuticals in Q1 2017 and has held it in 19 quarters since.
  • Marshall Wace North America's Vertex Pharmaceuticals position peaked at $236M in Q2 2018.
  • 935 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.